beta
Trial Radar AI
Clinical Trial NCT06957886 for HER2-low Breast Cancer is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer Phase 3 566 Randomized Open-Label

Recruiting
Clinical Trial NCT06957886 is designed to study Treatment for HER2-low Breast Cancer. It is a Phase 3 interventional study that is recruiting, having started on May 15, 2025, with plans to enroll 566 participants. Led by Sichuan Baili Pharmaceutical Co., Ltd., it is expected to complete by December 1, 2027. The latest data from ClinicalTrials.gov was last updated on January 21, 2026.
Brief Summary
This trial is a registered, phase III, randomized, open-label and multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with unresectable, locally recurrent or metastatic HER2-low breast cancer.
Official Title

A Randomized, Controlled Phase III Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Conditions
HER2-low Breast Cancer
Other Study IDs
  • BL-M07D1-304
NCT ID Number
NCT06957886
Start Date (Actual)
2025-05-15
Last Update Posted
2026-01-21
Completion Date (Estimated)
2027-12
Enrollment (Estimated)
566
Study Type
Interventional
PHASE
Phase 3
Status
Recruiting
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalBL-M07D1
Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
BL-M07D1
Administration by intravenous infusion for a cycle of 3 weeks.
Active Comparatorinvestigator's choice of chemotherapy
Participants receive Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel for the first cycle. Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel
Oral administration of Capecitabine. Administration by intravenous infusion of Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel.
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Progression-free survival (PFS)
Progression-free survival (PFS) as assessed by BICR is defined as the time between the date subjects were randomized and the first observation of disease progression (based on BICR's image-based assessment) or death.
Up to approximately 24 months
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Overall survival (OS)
Overall survival (OS) is defined as the time between the subject's randomization date and subject's death.
Up to approximately 24 months
Objective Response Rate (ORR)
Objective response rate (ORR) is defined as the number of CR and PR in the treatment and control groups divided by the number of that group in the full analysis set (FAS).
Up to approximately 24 months
Duration of Response (DOR)
Duration of Response (DOR) : defined as the period from the date when tumor response is first recorded to the date when objective tumor progression is first recorded or the date of death.
Up to approximately 24 months
Clinical Benefit Rate (CBR)
Clinical benefit ratio (CBR) is defined as the percentage of patients with advanced cancer who achieved complete remission, partial remission, or stable disease for at least 6 months after treatment.
Up to approximately 24 months
Disease Control Rate (DCR)
Disease Control Rate (DCR) : Percentage of all randomized subjects who rated the best overall response (BOR) as complete response (CR), partial response (PR), and disease stabilization (SD) according to RECIST 1.1 criteria.
Up to approximately 24 months
Treatment Emergent Adverse Event (TEAE)
TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-M07D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-M07D1.
Up to approximately 24 months
Anti-drug antibody (ADA)
Frequency of anti-BL-M07D1 antibody (ADA) will be investigated.
Up to approximately 24 months
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
Female
  1. Voluntarily sign the informed consent and follow the requirements of the protocol;
  2. Women aged ≥18 years and ≤75 years at the time of written informed consent;
  3. Expected survival time ≥12 weeks;
  4. Histologically or cytologically confirmed unresectable, locally recurrent or metastatic HER2-low breast cancer;
  5. Provide the latest tumor tissues to the central laboratory for HER2 and HR detection;
  6. Meet the treatment requirements in the plan;
  7. Must have at least one measurable target lesion that meets the RECIST v1.1 definition;
  8. ECOG 0 or 1;
  9. Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0;
  10. Organ function level must meet the requirements;
  11. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and must be non-lactating; All enrolled patients (male or female) should use adequate, highly effective contraception for the entire treatment cycle and for 7 months after completion of treatment.

  1. Received mitomycin C and nitrosourea chemotherapy within 6 weeks before the first dose, and received surgery or radical radiotherapy within 4 weeks before the first dose;
  2. Patients who were not suitable to use the control drugs chosen by the researchers because of intolerance to the chemotherapy drugs of the control group or other contraindications;
  3. Previous treatment with anti-HER2 drugs;
  4. Prior ADC drug therapy with camptothecin derivative as toxin;
  5. The history of severe cardiovascular and cerebrovascular diseases in the past six months was screened;
  6. Severe impairment of lung function due to concurrent pulmonary diseases;
  7. History of ILD/interstitial pneumonia requiring steroid therapy, current ILD/interstitial pneumonia or suspected ILD/interstitial pneumonia;
  8. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
  9. Other primary malignancies diagnosed within 5 years before the first dose;
  10. Poorly controlled hypertension;
  11. Patients with active central nervous system metastases;
  12. Patients with a history of severe allergy to any excipients or components of the study drug;
  13. History of autologous or allogeneic stem cell transplantation or organ transplantation;
  14. Anthracycline-equivalent cumulative dose of adriamycin > 360 mg/m2;
  15. Human immunodeficiency virus antibody positive, active hepatitis B virus infection, cirrhosis, or hepatitis C virus infection;
  16. Serious infection within 4 weeks before the first dose of study drug; Severe infection requiring antibiotic, antiviral or antifungal control at screening;
  17. Patients with massive effusions, or effusions with obvious symptoms, or poorly controlled effusions;
  18. Carcinomatous lymphangitis;
  19. Was receiving &gt before randomization; 10mg/d prednisone systemic corticosteroids or equivalent anti-inflammatory active drugs or any form of immunosuppressive therapy;
  20. The presence of a severe neurological or mental illness;
  21. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
  22. Intestinal obstruction, Crohn's disease, ulcerative colitis or chronic diarrhea;
  23. Subjects who are scheduled to receive live vaccine or receive live vaccine within 28 days before the first dose;
  24. Patients with other serious physical or laboratory abnormalities or poor compliance that may increase the risk of participating in the study or interfere with the results of the study, and patients who are considered by the investigators to be unsuitable for participating in the study.
Sichuan Baili Pharmaceutical Co., Ltd. logoSichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. logoBaili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Study Central Contact
Contact: Sa Xiao, PHD, 15013238943, [email protected]
2 Study Locations in 1 Countries

Guangdong

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
Herui Yao, Contact
Recruiting

Hunan

Hunan Cancer Hospital, Changsha, Hunan, China
Quchang Ouyang, Contact
Not yet recruiting